Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas
Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas
复制标题
DOI：
10.1002/ijc.23758
复制
发表时间：
2008-11-01
影响因子：
6.4
通讯作者：
Horvath, Gyoergy
中科院分区：
文献类型：
--
作者：
Partheen, Karolina;Levan, Kristina;Horvath, Gyoergy
卵巢癌患者的死亡率很高，可用的预后因素不足。生物标志物的使用可能有助于更好地预测这些患者的生存率。我们的目的是研究7种潜在生物标志物的基因和蛋白表达，以确定是否有可能将其用作预后因素。从我们先前的微阵列分析（2006）中选择的基因CLU、ITGB 3、TACC 1、MUC 5 B、CAPG、PRAME和TROAP在19个肿瘤中用定量实时聚合酶链反应（QPCR）进行分析。我们发现CLU和ITGB 3在存活者的肿瘤中表达更多，PRAME和CAPG在死亡患者的肿瘤中表达更多。其他3个基因的表达无显著差异。采用western blot半定量分析43例肿瘤组织中CLU、ITGB 3、PRAME和CAPG的蛋白表达。我们确定了mRNA和蛋白质表达相关，并且所有4种蛋白质的表达均显著不同。此外，免疫组织化学（IHC）用于定位肿瘤样品中蛋白质的表达。根据我们的研究结果，CLU、ITGB 3、PRAME和CAPG这4种生物标志物可作为III期浆液性卵巢腺癌患者的预后因素。(c)2008 Wiley-Liss，Inc.
The mortality rate for patients with ovarian carcinomas is high and the available prognostic factors are insufficient. The use of biomarkers may contribute to better prediction and survival for these patients. We aimed to study the gene and protein expressions for 7 potential biomarkers, to determine if it is possible to use them as prognostic factors. Genes selected from our previous microarray analysis (2006), CLU, ITGB3, TACC1, MUC5B, CAPG, PRAME and TROAP, were analyzed in 19 of the tumors with quantitative real-time polymerase chain reaction (QPCR). We found that CLU and ITGB3 were more expressed in tumors from survivors and PRAME and CAPG were more expressed in tumors from deceased patients. None of the other 3 genes were significantly differently expressed. The protein expressions of CLU, ITGB3, PRAME and CAPG were analyzed in 43 of the tumors with western blot for semiquantitative analysis. We established that the mRNA and protein expressions correlated and that all 4 proteins were significantly differently expressed. Further, immunohistochemistry (IHC) was used to localize the expression of the proteins in the tumor samples. According to our results, the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas. (c) 2008 Wiley-Liss, Inc.